This company has been marked as potentially delisted and may not be actively trading. Interpace Biosciences (IDXG) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesTrendsBuy This Stock IDXG vs. DGX, LH, DVA, CHE, CRVL, AMED, MD, AMN, CCRN, and PAVMShould you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include Quest Diagnostics (DGX), Laboratory Co. of America (LH), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Amedisys (AMED), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), and PAVmed (PAVM). Interpace Biosciences vs. Quest Diagnostics Laboratory Co. of America DaVita Chemed CorVel Amedisys Pediatrix Medical Group AMN Healthcare Services Cross Country Healthcare PAVmed Quest Diagnostics (NYSE:DGX) and Interpace Biosciences (NASDAQ:IDXG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Which has more risk and volatility, DGX or IDXG? Quest Diagnostics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Does the media favor DGX or IDXG? In the previous week, Quest Diagnostics had 18 more articles in the media than Interpace Biosciences. MarketBeat recorded 18 mentions for Quest Diagnostics and 0 mentions for Interpace Biosciences. Quest Diagnostics' average media sentiment score of 1.22 beat Interpace Biosciences' score of 0.00 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Quest Diagnostics Positive Interpace Biosciences Neutral Do analysts prefer DGX or IDXG? Quest Diagnostics presently has a consensus target price of $185.07, suggesting a potential upside of 4.25%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Quest Diagnostics is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quest Diagnostics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.69Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in DGX or IDXG? Quest Diagnostics received 225 more outperform votes than Interpace Biosciences when rated by MarketBeat users. However, 72.83% of users gave Interpace Biosciences an outperform vote while only 49.14% of users gave Quest Diagnostics an outperform vote. CompanyUnderperformOutperformQuest DiagnosticsOutperform Votes54449.14% Underperform Votes56350.86% Interpace BiosciencesOutperform Votes31972.83% Underperform Votes11927.17% Do insiders and institutionals hold more shares of DGX or IDXG? 88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 8.2% of Quest Diagnostics shares are held by insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, DGX or IDXG? Quest Diagnostics has higher revenue and earnings than Interpace Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuest Diagnostics$10.16B1.95$871M$7.9122.44Interpace Biosciences$40.21M0.07$800KN/AN/A Is DGX or IDXG more profitable? Interpace Biosciences has a net margin of 10.39% compared to Quest Diagnostics' net margin of 8.80%. Quest Diagnostics' return on equity of 15.07% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Quest Diagnostics8.80% 15.07% 6.72% Interpace Biosciences 10.39%-8.09%37.14% SummaryQuest Diagnostics beats Interpace Biosciences on 13 of the 17 factors compared between the two stocks. Get Interpace Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXG vs. The Competition Export to ExcelMetricInterpace BiosciencesSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.96M$4.38B$5.53B$7.98BDividend YieldN/A46.07%5.37%4.22%P/E RatioN/A29.5922.5618.86Price / Sales0.0755.86402.16106.71Price / Cash1.9951.0838.1834.62Price / Book-0.056.166.764.32Net Income$800,000.00$68.15M$3.22B$247.98M Interpace Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXGInterpace BiosciencesN/A$0.67-8.1%N/A-52.5%$2.96M$40.21M0.00152Gap DownDGXQuest Diagnostics4.6456 of 5 stars$177.22+0.3%$185.07+4.4%+29.5%$19.76B$10.16B23.0249,000Short Interest ↑Positive NewsLHLaboratory Co. of America4.4375 of 5 stars$235.11+2.4%$268.77+14.3%+23.1%$19.68B$13.01B26.6775,500Earnings ReportInsider TradeAnalyst RevisionNews CoveragePositive NewsDVADaVita4.3459 of 5 stars$140.70+0.1%$166.33+18.2%+4.8%$11.27B$12.82B13.1170,000Upcoming EarningsPositive NewsCHEChemed4.5804 of 5 stars$577.64+2.1%$674.00+16.7%+2.5%$8.43B$2.49B29.1314,200Positive NewsCRVLCorVel0.9291 of 5 stars$107.41-2.1%N/A+38.6%$5.52B$871.31M63.184,230Positive NewsAMEDAmedisys2.9398 of 5 stars$94.71+0.0%$100.75+6.4%+4.3%$3.11B$2.37B37.5820,000Positive NewsMDPediatrix Medical Group1.9426 of 5 stars$12.49+1.0%$16.75+34.1%+38.7%$1.07B$2.01B-10.427,850Upcoming EarningsNews CoveragePositive NewsAMNAMN Healthcare Services4.2569 of 5 stars$19.95+3.1%$38.67+93.8%-64.3%$762.06M$2.98B-5.184,230CCRNCross Country Healthcare3.6052 of 5 stars$13.51flat$18.41+36.2%-18.4%$442.94M$1.34B-270.152,700Upcoming EarningsPositive NewsPAVMPAVmed4.4052 of 5 stars$0.76+4.9%$19.50+2,482.8%-61.8%$12.91M$3.00M-0.1790Gap Down Related Companies and Tools Related Companies Quest Diagnostics Competitors Laboratory Co. of America Competitors DaVita Competitors Chemed Competitors CorVel Competitors Amedisys Competitors Pediatrix Medical Group Competitors AMN Healthcare Services Competitors Cross Country Healthcare Competitors PAVmed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDXG) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IDXG Stock Free IDXG Stock Alerts